Trial Profile
A Phase I/II Basket Trial Evaluating a Combination of Metronomic Oral Vinorelbine Plus Anti-PD-L1/Anti-CTLA4 ImmunothErapy in Patients With Advanced Solid Tumour
Status:
Active, no longer recruiting
Phase of Trial:
Phase I/II
Latest Information Update: 12 Jan 2024
Price :
$35
*
At a glance
- Drugs Durvalumab (Primary) ; Tremelimumab (Primary) ; Vinorelbine (Primary)
- Indications Advanced breast cancer; Carcinoma; Cervical cancer; Head and neck cancer; Male breast cancer; Prostate cancer; Solid tumours; Squamous cell cancer
- Focus Adverse reactions; Therapeutic Use
- Acronyms MOVIE
- 13 Sep 2022 Results (n=39) of tumor mutational burden-high and/or microsatellite instability-high cohort were presented at the 47th European Society for Medical Oncology Congress.
- 28 Jan 2022 Planned primary completion date changed from 14 Jan 2022 to 14 May 2022.
- 21 Sep 2021 Primary endpoint (CBR-24week) has been met, as per result presented at the 46th European Society for Medical Oncology Congress.